The $26 central target is calculated from five current, attributable analyst targets. The most bullish is H.C. Wainwright at $32 (Buy, maintained November 5, 2026), while the most cautious is Canaccord Genuity at $21 (Buy, reiterated November 3, 2026). In between, Craig-Hallum holds $24 (Buy, raised from $18 on August 7, 2026), BTIG's Marie Thibault holds $25 (Buy, raised from $21 on November 9, 2026), and Clear Street holds $27 (Buy). The simple average of these five figures is about $25.8, rounded to a clean $26 for this analysis.
Every reviewed firm rates the stock a Buy, which third-party aggregators commonly summarize as a "Strong Buy" analyst consensus. However, the $21-to-$32 spread is unusually wide for a small-cap name, reflecting genuine disagreement over how quickly HEPZATO adoption and future label expansions will convert into revenue and earnings. None of these figures is a guarantee, and the mean should not be read as an official published consensus.
As of the November 9, 2026 close, Delcath Systems, Inc. (DCTH) traded at $20.27, up sharply after third-quarter results, with a market capitalization near $703 million and a 52-week range of roughly $8.12 to $20.30. Reaching $26 would require about a 28% advance — a substantial, though not extreme, move for a volatile, high-growth medical-device stock.
The path would most likely depend on sustained HEPZATO KIT revenue growth in metastatic uveal melanoma, continued expansion of U.S. treatment centers, and progress toward broader indications such as liver-dominant metastatic colorectal cancer, where the company has cleared an investigational new drug application for a Phase 2 trial. Valuation is a wildcard: with trailing EPS near zero, the stock trades on forward revenue expectations rather than earnings, making sentiment and guidance revisions unusually important.
The stock broke to a fresh 52-week high around $20.30 on November 9, 2026, clearing a prior resistance zone near $18–$18.23. That former ceiling may now act as a support level on pullbacks, with the round-number $20 area as a nearby psychological marker. The 52-week low of $8.12 sits far below, underscoring the stock's wide trading range. A sustained hold above $20 would strengthen the technical case for a move toward the $24–$26 area, while a failure back below $18 would suggest the breakout lacked conviction.
Analyst price targets typically reflect a roughly 12-month research horizon, though individual firms do not always disclose an exact timeframe. The most relevant near-term items are quarterly revenue and patient-start trends, any updates to guidance, analyst target revisions following results, and milestones in the colorectal cancer and other expansion programs. Investors should also watch treatment-center additions and any changes to the competitive or regulatory landscape.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals from changing market conditions, technical behavior, and AI-driven analysis. The tool is designed to help traders discover opportunities, track positions, and identify shifting trends more efficiently than manual screening alone. Because signals update with market data, they can serve as a complementary lens to traditional fundamental research rather than a replacement for it. Traders looking to streamline their daily workflow may want to review the AI Daily Buy/Sell Signals to see how the system currently assesses DCTH.
The $26 central target — the mean of five Buy-rated analyst targets spanning $21 to $32 — implies a substantial, roughly 28% move from the latest close of $20.27. The strongest arguments for such a move are accelerating HEPZATO revenue, raised guidance, positive clinical data, and a widening label-expansion pipeline. The principal obstacles are a demanding valuation, concentration in a single product and indication, seasonal revenue lumpiness, and execution risk. With unanimous Buy ratings but a very wide target range, the market is clearly optimistic about direction yet uncertain about magnitude. Whether DCTH reaches $26 will hinge on continued commercial execution and credible progress toward broader indications, which investors should monitor closely.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, DCTH has been loosely correlated with SGHT. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if DCTH jumps, then SGHT could also see price increases.
| Ticker / NAME | Correlation To DCTH | 1D Price Change % | ||
|---|---|---|---|---|
| DCTH | 100% | -2.34% | ||
| SGHT - DCTH | 40% Loosely correlated | -4.14% | ||
| PRCT - DCTH | 38% Loosely correlated | -4.08% | ||
| NVST - DCTH | 38% Loosely correlated | -1.55% | ||
| RXST - DCTH | 36% Loosely correlated | -3.04% | ||
| BWAY - DCTH | 36% Loosely correlated | -2.86% | ||
More | ||||
| Ticker / NAME | Correlation To DCTH | 1D Price Change % |
|---|---|---|
| DCTH | 100% | -2.34% |
| Health Services category (238 stocks) | 7% Poorly correlated | -2.69% |
| Medical/Nursing Services category (138 stocks) | 6% Poorly correlated | -3.38% |